Lundbeck is a global pharmaceutical company conducting research into developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders of the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington's disease, epilepsy and insomnia.
Research and development
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ 1,400 highly trained specialists in our research and development units. Each year, Lundbeck ploughs back about 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain disorders.
Products
Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS). The most recently launched compounds include: Cipralex®/Lexapro® (depression), Ebixa® (Alzheimer’s disease), Azilect® (Parkinson’s disease), Xenazine® (chorea associated with Huntington's disease), Serdolect® (schizophrenia) and Sabril® (epilepsy).
Karin de Laine
» KDL@Lundbeck.com
» www.lundbeck.com |